Researchers are testing whether eating all meals within an 8-hour window might help multiple myeloma patients respond better to chemotherapy. A 2024 randomized feasibility trial called FASTINA will follow 54 patients to determine if this time-restricted eating pattern is safe and practical during cancer treatment, with results expected in 2026. While lab studies suggest fasting could make cancer cells more vulnerable to drugs, this early-stage research focuses on feasibility rather than proving effectiveness.
Researchers are testing whether time-restricted eating—eating all your food within an 8-hour window each day—might help people with multiple myeloma (a type of blood cancer) respond better to chemotherapy. According to Gram Research analysis, this early-stage study will follow 54 patients to see if this eating pattern is safe and practical to follow during cancer treatment. While lab studies suggest fasting might make cancer cells more vulnerable to drugs, doctors want to make sure this approach actually works in real patients before recommending it widely.
Key Statistics
The FASTINA trial, a 2024 randomized controlled feasibility study of 54 multiple myeloma patients, will test whether 16:8 time-restricted eating combined with nutrition counseling improves treatment response compared to nutrition counseling alone over 12 weeks.
Researchers in the FASTINA study set an adherence target of at least 80% compliance with the 8-hour eating window as a primary measure of feasibility in multiple myeloma patients undergoing active chemotherapy.
The FASTINA trial will track complete response with MRD (measurable residual disease) negativity as a primary endpoint to explore whether time-restricted eating generates preliminary signals of improved cancer treatment response in multiple myeloma patients.
The Quick Take
- What they studied: Whether eating all meals within an 8-hour window (called 16:8 time-restricted eating) combined with nutrition counseling helps multiple myeloma patients respond better to their cancer drugs compared to nutrition counseling alone.
- Who participated: 54 adults with multiple myeloma who are starting chemotherapy treatment. Half will try time-restricted eating plus nutrition advice, and half will receive nutrition advice only.
- Key finding: This is a feasibility study, meaning researchers are primarily checking if patients can actually stick with this eating pattern (aiming for at least 80% adherence) and whether it’s safe during cancer treatment, rather than proving it works better.
- What it means for you: If you have multiple myeloma, this research is still very early. Don’t change your eating habits based on this study alone. Talk to your cancer doctor before trying time-restricted eating, as it may not be appropriate for everyone undergoing chemotherapy.
The Research Details
FASTINA is a randomized controlled feasibility trial, which means researchers will randomly assign 54 multiple myeloma patients into two groups. One group will eat all their food within an 8-hour window each day (like 10 AM to 6 PM) while also receiving nutrition counseling from a dietitian. The other group will receive the same nutrition counseling but can eat normally throughout the day. Both groups will continue their regular cancer treatment as prescribed by their doctors.
The study will last 12 weeks and track how well patients stick to their assigned eating pattern, how their cancer responds to treatment, any side effects they experience, changes in their body weight and muscle, and how they feel overall. Researchers chose this design because while lab studies suggest fasting might make cancer cells more vulnerable to chemotherapy drugs, very little real-world data exists in blood cancer patients like those with multiple myeloma.
This is called a ‘feasibility’ study because the main goal isn’t to prove the eating pattern works better—it’s to figure out if it’s practical and safe enough to test in a larger study later. Think of it like testing a new recipe before serving it to a big dinner party.
Multiple myeloma is a serious cancer that keeps coming back and becomes harder to treat each time. Doctors need new ways to help their drugs work better. This study design is important because it carefully tests whether time-restricted eating is something patients can actually do while sick and undergoing chemotherapy, and whether it causes any new problems. If this small study shows promise and safety, it could lead to larger studies that might prove whether this approach really improves treatment outcomes.
This is a well-designed early-stage study registered in an official clinical trial database before it started, which is a good sign of scientific rigor. However, because it’s small (only 54 patients) and focuses on feasibility rather than proving effectiveness, the results won’t be definitive. The study is ‘open-label,’ meaning both patients and doctors know who is doing time-restricted eating, which could influence results. Results from this study should be viewed as preliminary and hypothesis-generating rather than conclusive proof.
What the Results Show
This is a protocol paper describing the study plan rather than actual results, so we don’t yet know the outcomes. However, the researchers have clearly defined what they’re looking for: they want to see if at least 80% of patients in the time-restricted eating group can stick with eating only during an 8-hour window for the full 12 weeks. They’ll also measure whether patients achieve ‘complete response with MRD negativity,’ which is a specific marker showing that cancer treatment worked well.
The study will also track how many patients experience serious side effects (grade 3 or worse) and whether time-restricted eating causes any unexpected problems during chemotherapy. Researchers will measure changes in body weight, muscle mass, energy levels, and quality of life. They’ll follow patients to see how long they stay cancer-free and track their overall survival, though these are exploratory measures in this small study.
Because this is a feasibility study, the main value will be learning whether this approach is practical and safe enough to test in a larger group of patients. Even if the results don’t show a clear benefit, proving that patients can safely follow time-restricted eating during cancer treatment would be valuable information for future research.
Beyond the main goals, researchers will examine how well the cancer responds to treatment in both groups, looking at different measures of treatment success. They’ll assess nutritional status to make sure patients aren’t becoming malnourished from the restricted eating window. Changes in body composition—specifically muscle mass versus fat—will be tracked, since maintaining muscle is important for cancer patients. Quality of life measures and fatigue levels will help show whether time-restricted eating affects how patients feel day-to-day during treatment.
Lab studies have suggested that fasting-related metabolic changes might make cancer cells more vulnerable to chemotherapy by creating nutrient-poor conditions that cancer cells struggle to survive in. Some clinical studies in solid tumors (like breast cancer) have explored time-restricted eating, but results have been mixed and mainly showed feasibility and possible reduction in side effects rather than clear improvements in treatment response. This study is important because there’s almost no data on whether this approach works in blood cancers like multiple myeloma, making it a genuine gap in medical knowledge.
This is a small study with only 54 patients at a single center, so results may not apply to all multiple myeloma patients. The study is ‘open-label,’ meaning patients and doctors know who is doing time-restricted eating, which could create bias in how they perceive results. The 12-week timeframe is relatively short for cancer research. Because it’s a feasibility study, it’s not designed to prove whether time-restricted eating actually improves survival or treatment response—it’s designed to see if a larger study is even possible. Results won’t be available until the study completes, likely in 2026 or later.
The Bottom Line
This research is too early to make recommendations for patients. If you have multiple myeloma and are interested in time-restricted eating, discuss it with your oncologist before making any changes. Your doctor knows your specific situation and can advise whether this approach might be appropriate for you. Do not attempt time-restricted eating during chemotherapy without medical supervision, as it could interfere with your treatment or nutrition.
Multiple myeloma patients and their doctors should follow this research as it develops. Oncologists interested in supportive care and metabolic approaches to cancer treatment should watch for results. People interested in fasting and cancer should understand that this is preliminary research and not yet applicable to general practice. This study is not relevant for people without multiple myeloma or those not undergoing active chemotherapy.
This study began in 2024 and will run for 12 weeks of patient participation. Results likely won’t be published until 2026 or 2027. Even if results are positive, it would take several more years of larger studies before time-restricted eating might become a standard recommendation for multiple myeloma patients. Don’t expect changes to cancer treatment protocols based on this single feasibility study.
Frequently Asked Questions
Can fasting help cancer treatment work better?
Lab studies suggest fasting might make cancer cells more vulnerable to chemotherapy, but real-world evidence in cancer patients is limited. The FASTINA trial is testing this in multiple myeloma patients, with results expected in 2026. Don’t attempt fasting during cancer treatment without your doctor’s approval.
Is time-restricted eating safe during chemotherapy?
The FASTINA study is specifically designed to answer this question by monitoring 54 multiple myeloma patients for safety and side effects. Early results from other cancer types suggest it may be feasible, but individual tolerance varies greatly. Always consult your oncologist before trying any dietary changes during treatment.
What is time-restricted eating and how does it work?
Time-restricted eating means consuming all food within a specific window, typically 8 hours (like 10 AM to 6 PM), and fasting the remaining 16 hours. The theory is that fasting periods create metabolic changes that might make cancer cells more vulnerable to chemotherapy drugs by limiting nutrient availability.
Who should consider time-restricted eating if they have cancer?
Only multiple myeloma patients whose oncologist specifically recommends it should consider this approach. This research is too early to recommend for other cancer types. Never start time-restricted eating during cancer treatment without explicit approval from your cancer care team, as it could affect nutrition and treatment tolerance.
When will we know if time-restricted eating helps multiple myeloma patients?
The FASTINA feasibility study will complete in 2026, but results won’t be published immediately. Even positive feasibility results would require larger studies before time-restricted eating could become a standard recommendation. Expect 3-5 years minimum before any potential clinical practice changes.
Want to Apply This Research?
- If a user has multiple myeloma and their doctor approves time-restricted eating, track daily adherence to the eating window (e.g., 10 AM to 6 PM) with a yes/no log, plus record energy levels, appetite, and any side effects on a 1-10 scale to share with their oncology team.
- For users interested in time-restricted eating during cancer treatment, the practical change would be: set phone reminders for eating window start and end times, plan meals in advance to ensure adequate nutrition within the window, and log any difficulty sticking to the schedule to discuss with their doctor.
- Long-term tracking should include weekly adherence percentages, monthly body weight checks (with doctor approval), ongoing side effect monitoring, and regular check-ins with the oncology team about whether time-restricted eating is helping or hindering treatment tolerance.
This article describes a feasibility study protocol and does not report final results. Time-restricted eating during cancer treatment is experimental and not yet standard medical practice. Multiple myeloma patients should not attempt time-restricted eating without explicit approval from their oncology team. This research is preliminary and should not be used to make treatment decisions. Always consult with your cancer doctor before making any dietary changes during chemotherapy. Results from this small feasibility study cannot be generalized to all patients and do not prove effectiveness.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.